Diabetes Centre Mergentheim
Bad Mergentheim, 97980, Germany
NCT Number: NCT02748239
A new diabetes education program for the initiation of non-intensive insulin therapy in type 2 diabetic patients (MEDIAS 2 CT) was developed.
In the evaluation, this new developed program is compared with an education programs which is currently used for diabetes education. It is expected that the new developed program (MEDIAS 2 CT) can demonstrate non-inferiority with regard to the main outcome variable glycemic control. If non-inferiority can be demonstrated superiority of this program will be tested.
Looking for future studies?
Notify Me18 year–75 year
All sexes
Interventional
Not applicable
Bad Mergentheim, 97980, Germany
The MEDIAS 2 CT program is based on a self-management/empowerment approach. It is conducted as a group program comprising 6 lessons of 90 minutes each. MEDIAS 2 CT was designed to help patients perform conventional insulin therapy. In addition, MEDIAS 2 CT focused on controlling metabolic risk factors (elevated lipids and blood pressure), coping with the risk of late complications, and reducing the emotional burden of diabetes and its treatment.
The active comparator condition (ACC-CT) consisted of an established patient education program for type 2 diabetic patients with conventional insulin treatment. This education program was developed in the 1980s and 1990s and is more didactic-oriented, focusing primarily on the acquisition of knowledge, skills, and information about the correct treatment of diabetes. Both treatment arms (MEDIAS 2 CT and ACC) consisted of 6 lessons, which were conducted as group sessions.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The MEDIAS 2 CT is a education program for the initiation of a conventional insulin therapy in type 2 diabetic patients. The program consists of 6 lessons and is conducted in group settings (4-8 participants).
The Current CT program is currently used for the initiation of conventional insulin therapy in type 2 diabetic patients. The program consists of 6 lessons and is conducted in group settings (4-8 participants).
Time frame: six months follow up after termination of the programs
Time frame: six months follow up
QoL will be assessed using the Short Form Health Survey (SF-12) questionnaire.
Time frame: six months follow up
A diabetes knowledge test for insulin treatment in type 2 diabetes will be used
Time frame: six months follow up
Diabetes related emotional burden / diabetes related distress will be assessed using the Problem Areas in Diabetes (PAID) questionnaire
Time frame: six months follow up
Second questionnaire for assessing diabetes related distress is the Diabetes Distress Scale (DDS)
Time frame: six months follow up
The Summary of Diabetes Self-Care Activities (SDSCA) scale will be used.
Time frame: six months follow up
The German version of the Center of Epidemiological Studies Depression Scale (CES-D) will be used.
Forschungsinstitut der Diabetes Akademie Mergentheim
Other
Evaluation of a Self-management Oriented Diabetes Education Program for the Initiation of Non-Intensive Insulin Therapy in Type 2 Diabetic Patients
Acronym: MEDIAS-2-CT
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05929079
Apnea, Body Weight
Anniston, Alabama, United States
View Trial DetailsNCT06649344
Diabetes Mellitus, Diabetes Mellitus, Type 2
Tianjin, Tianjin Municipality, China
View Trial DetailsNCT07732218
Diabetes Mellitus, Diabetes Mellitus, Type 2
Peshawar, Khyber Pakhtunkhwa, Pakistan
View Trial DetailsNCT05351359
Diabetes Mellitus, Diabetes Mellitus, Type 2
Prague, Czechia
View Trial Details